Macular Degeneration

What is Macular Degeneration?
Macular Degeneration is a group of progressive eye conditions which involve deterioration of the macula, the central region of the retina.

Age-Related Macular Degeneration
By Tom Boyles, Dustin Broadus, Lori Buckle, Constance Marsh, and April Seybold
http://www.faculty.sfasu.edu/munromicha/spe516/macular_degeneration_09.ppt

Age-Related Macular Degeneration
Sabrina Carter & Kori Eakin
http://www.faculty.sfasu.edu/munromicha/spe516/amd9.ppt

Antioxidants and Nutrients in the Treatment and Prevention of Age-Related Macular Degeneration
Michael B. Gorin, M.D. Ph.D.
http://www.healthyaging.pitt.edu/seminars2006/nutritionsymposium/gorin-Nutrition-AMDlecture.ppt

Age Related Macular Degeneration
http://www.fpm.emory.edu/Family/didactics/powerpint/AFP%20Journal%20Review%205-15-08(2).ppt

Macular Degeneration
http://www.mccc.edu/~martinl/documents/M21fVISUALALTERATIONSmaculardegeneration.ppt

Advances in the Treatment of Age-Related Macular Degeneration (AMD)
Michael E. Helm, PA-S
AMD.ppt

Visual Impairment
Visual Impairment.ppt

Career Counseling for Clients who Are Blind or Visually Impaired
Lauri Dishman, M.A., LCPC
Career_Counseling_for_People_with_Vision_Loss.ppt

 Eye disorders
Eye disorders.ppt

Telescopic Implants
Joseph Cullen
Telescopic Implants.ppt

The Impact of Cataract Surgery in Patients with Low Vision
Clinical Research Methods
Irene C. Kuo, MD
The Impact of Cataract Surgery in Patients with Low Vision.ppt

Making Sense of Sensory Losses as We Age
Dena Kemmet, M.S. and Sean Brotherson, Ph.D.
Making Sense of Sensory Losses as We Age.ppt

The Eyes Have It!
Eyes_have_it/can_you_tell_the_difference.ppt

Vision II
S. Buckley RN, MSN
visiontwo.ppt
200 scholarly publications free access

1. Comprehensive analysis of copy number variation of genes at chromosome 1 and 10 Loci associated with late age related macular degeneration.
2. New approaches and potential treatments for dry age-related macular degeneration.
3. Is age-related macular degeneration a problem in Ibadan, Sub-Saharan Africa?
4. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD).
5. Multicenter cohort association study of SLC2A1 single nucleotide polymorphisms and age-related macular degeneration.
6. New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration.
7. Characteristics of patients with wet age-related macular degeneration and low intake of lutein and zeaxanthin.
8. Cyclic intensive light exposure induces retinal lesions similar to age-related macular degeneration in APPswe/PS1 bigenic mice.
9. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size.
10. Nutritional Supplements for Age-Related Macular Degeneration: A Systematic Review Internet.
11. Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD).
12. Transcriptome changes in age-related macular degeneration.
13. Copy number variation of age-related macular degeneration relevant genes in the Korean population.
14. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
15. Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control study.
16. Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration.
17. The past, present, and future of exudative age-related macular degeneration treatment.
18. The estimated prevalence and incidence of late stage age related macular degeneration in the UK.
19. Genetics of immunological and inflammatory components in age-related macular degeneration.
20. TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration.
21. Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
22. The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration.
23. Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants.
24. Chlamydia infection status, genotype, and age-related macular degeneration.
25. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the lucentis genotype study (an American Ophthalmological Society thesis).
26. Population differences in genetic risk for age-related macular degeneration and implications for genetic testing.
27. Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2).
28. Bevacizumab injection in patients with age-related macular degeneration associated with poor initial visual acuity.
29. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
30. One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration.
31. Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.
32. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study.
33. A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population.
34. Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration.
35. Decoding simulated neurodynamics predicts the perceptual consequences of age-related macular degeneration.
36. Antiangiogenic treatment in age-related macular degeneration in patients with a history of cerebrovascular risk.
37. Characterisation of a C1qtnf5 Ser163Arg knock-in mouse model of late-onset retinal macular degeneration.
38. Analysis of candidate genes for age-related macular degeneration subtypes in the Japanese population.
39. Associations between genetic polymorphisms of insulin-like growth factor axis genes and risk for age-related macular degeneration.
40. Pharmacogenetics and age-related macular degeneration.
41. Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration.
42. Age-related macular degeneration in Onitsha, Nigeria.
43. A 32 kb critical region excluding Y402H in CFH mediates risk for age-related macular degeneration.
44. Age-related macular degeneration and smoking cessation advice by eye care providers: a pilot study.
45. Complement factor D in age-related macular degeneration.
46. Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology.
47. The chronic care for age-related macular degeneration study (CHARMED): study protocol for a randomized controlled trial.
48. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration.
49. Embryonic stem cell implantation for the treatment of Stargardt’s disease and macular degeneration.
50. Quality of optometry referrals to neovascular age-related macular degeneration clinic: a prospective study.
51. Update on the role of genetics in the onset of age-related macular degeneration.
52. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study.
53. Imaging geographic atrophy in age-related macular degeneration.
54. Simple estimation of clinically relevant lesion volumes using spectral domain-optical coherence tomography in neovascular age-related macular degeneration.
55. Combined treatment of photodynamic therapy and bevacizumab for choroidal neovascularization secondary to age-related macular degeneration.
56. Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina.
57. Copy number variation in the complement factor H-related genes and age-related macular degeneration.
58. Lipids, lipoproteins, and age-related macular degeneration.
59. Treatment of wet age-related macular degeneration with ranibizumab in clinical practice: results and prognostic factors.
60. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration.
61. The macular degeneration of Edward Degas.
62. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration.
63. Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups.
64. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
65. Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration.
66. Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration.
67. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.
68. Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics.
69. Automatic detection of diabetic retinopathy and age-related macular degeneration in digital fundus images.
70. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration.
71. Multifocal electroretinogram findings after intravitreal bevacizumab injection in choroidal neovascularization of age-related macular degeneration.
72. Age-related macular degeneration.
73. An association between polymorphism of the heme oxygenase-1 and -2 genes and age-related macular degeneration.
74. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration.
75. Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin.
76. Pattern electroretinography in age-related macular degeneration.
77. Retinal pigment epithelium tears secondary to age-related macular degeneration: a simultaneous confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography study.
78. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.
79. Apolipoprotein E gene and age-related macular degeneration in a Chinese population.
80. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
81. Complement factor B polymorphism 32W protects against age-related macular degeneration.
82. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
83. Association between the SERPING1 gene and age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese.
84. Evaluation of variants in the selectin genes in age-related macular degeneration.
85. Vitamin D status and early age-related macular degeneration in postmenopausal women.
86. Detection of heat shock protein 70 in choroidal neovascular membranes secondary to age related macular degeneration.
87. Age-related macular degeneration and the other double helix. The Cogan Lecture.
88. Using genetic variation and environmental risk factor data to identify individuals at high risk for age-related macular degeneration.
89. Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration.
90. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration.
91. Gene transfer for neovascular age-related macular degeneration.
92. The A Allele of the -576G>A polymorphism of the transferrin gene is associated with the increased risk of age-related macular degeneration in smokers.
93. Age-Related Macular Degeneration (AMD).
94. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors.
95. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration.
96. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration.
97. The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age-related macular degeneration.
98. Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration.
99. Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration.
100. Angiogenin in age-related macular degeneration.
101. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.
102. Diabetes mellitus and early age-related macular degeneration.
103. Radiation therapy for neovascular age-related macular degeneration.
104. Computational quantification of complex fundus phenotypes in age-related macular degeneration and Stargardt disease.
105. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration.
106. Effect of bilateral macular scotomas from age-related macular degeneration on reach-to-grasp hand movement.
107. Mitochondrial DNA damage and repair in RPE associated with aging and age-related macular degeneration.
108. Copy number variations in candidate genes in neovascular age-related macular degeneration.
109. Development of polypoidal lesions in age-related macular degeneration.
110. SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.
111. Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration.
112. Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.
113. Wet versus dry age-related macular degeneration in patients with central field loss: different effects on maximum reading speed.
114. Prevalence of age-related macular degeneration in the US population.
115. Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration.
116. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
117. Elevated C-reactive protein levels and ARMS2/HTRA1 gene variants in subjects without age-related macular degeneration.
118. Segmentation and quantification of retinal lesions in age-related macular degeneration using polarization-sensitive optical coherence tomography.
119. Natural evolution and surgical outcome of massive subretinal haemorrhage in a patient with neovascular age-related macular degeneration on warfarin therapy.
120. Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration.
121. Laser treatment in 341 patients with exudative age-related macular degeneration.
122. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.
123. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration.
124. Dissection of chromosome 16p12 linkage peak suggests a possible role for CACNG3 variants in age-related macular degeneration susceptibility.
125. Are lung disease and function related to age-related macular degeneration?
126. Morphometric analysis of corneal endothelium after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment.
127. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.
128. Plasma oxidized LDL and thiol-containing molecules in patients with exudative age-related macular degeneration.
129. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration.
130. Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections.
131. Detection of macular function changes in early (AREDS 2) and intermediate (AREDS 3) age-related macular degeneration.
132. Healthy lifestyles related to subsequent prevalence of age-related macular degeneration.
133. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.
134. Associations of smoking, body mass index, dietary lutein, and the LIPC gene variant rs10468017 with advanced age-related macular degeneration.
135. The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage.
136. Lack of association of CFD polymorphisms with advanced age-related macular degeneration.
137. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.
138. Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study.
139. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration.
140. Scene perception in age-related macular degeneration.
141. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.
142. Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab.
143. Nutrition and age-related macular degeneration.
144. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.
145. Figure ground discrimination in age-related macular degeneration.
146. Comparison of an expanded ataxia interactome with patient medical records reveals a relationship between macular degeneration and ataxia.
147. Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration.
148. The ERCC6 gene and age-related macular degeneration.
149. Fixation stability during binocular viewing in patients with age-related macular degeneration.
150. Prospective study of common variants in the retinoic acid receptor-related orphan receptor α gene and risk of neovascular age-related macular degeneration.
151. Outer retinal cysts in exudative age-related macular degeneration: a spectral domain OCT study.
152. Age-related macular degeneration: genetic and environmental factors of disease.
153. Evidence for enhanced tissue factor expression in age-related macular degeneration.
154. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography.
155. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.
156. Improving function in age-related macular degeneration: design and methods of a randomized clinical trial.
157. Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.
158. A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice.
159. Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration.
160. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
161. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration.
162. Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration.
163. Prevention of age-related macular degeneration.
164. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization.
165. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD).
166. Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases.
167. The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence.
168. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres.
169. Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial.
170. Preoperative conjunctival bacterial microbiota of antiangiogenic intravitreous injection for age-related macular degeneration compared to cataract surgery preoperative microbiota.
171. Different populations of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into pathogenesis.
172. The controversy over the association between statins use and progression of age-related macular degeneration: a mini review.
173. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration.
174. Pars plana posterior capsulotomy in a patient with a telescope prosthesis for age-related macular degeneration.
175. Age-related macular degeneration.
176. Impact of age-related macular degeneration on vision-specific quality of life: Follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures.
177. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration.
178. Long-chain and very long-chain polyunsaturated fatty acids in ocular aging and age-related macular degeneration.
179. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration.
180. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration.
181. Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.
182. Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization.
183. Hyperopic refractive error and shorter axial length are associated with age-related macular degeneration: the Singapore Malay Eye Study.
184. Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab.
185. R102G polymorphism of the C3 gene associated with exudative age-related macular degeneration in a French population.
186. Age-related macular degeneration-associated variants at chromosome 10q26 do not significantly alter ARMS2 and HTRA1 transcript levels in the human retina.
187. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina.
188. Patient selection criteria for pilot studies on amelioration of non-neovascular age-related macular degeneration.
189. Cigarette smoke-related hydroquinone induces filamentous actin reorganization and heat shock protein 27 phosphorylation through p38 and extracellular signal-regulated kinase 1/2 in retinal pigment epithelium: implications for age-related macular degeneration.
190. Quality of Vision Index: a new method to appraise visual function changes in age-related macular degeneration.
191. Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration.
192. Incomplete cortical reorganization in macular degeneration.
193. Variations in TIMP3 are associated with age-related macular degeneration.
194. Complement factor h autoantibodies and age-related macular degeneration.
195. Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent.
196. Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration.
197. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation.
198. Cholesterol oxidation in the retina: implications of 7KCh formation in chronic inflammation and age-related macular degeneration.
199. Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration.
200. Causes of interruption of bevacizumab therapy in age-related macular degeneration.